# Safer Approaches to CRC Chemoprevention

> **NIH NIH R01** · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2021 · $217,481

## Abstract

Abstract/Summary
Administrative Supplement toR01 CA213987 “Safer approaches to CRC Chemoprevention”
Understanding genomic and metabolomic risk factors of CRC in American Indians Vs Caucasians
of Oklahoma.
This application responds to the PA-18-842 “Administrative Supplements to Support Cancer Disparity
Collaborative Research”, and is focused on colorectal cancer (CRC). The long- term goal is to improve
community and clinical CRC-related practice for American Indians (AIs) and African Americans (AAs)
compared to that of Caucasians (mainly non-Hispanic whites) in Oklahoma. CRC is the second most
common cause of cancer-related deaths in both Oklahomans and the US population as a whole. In
general, Oklahomans have higher incidence and mortality for most cancers – this is particularly so for
CRC where deaths are >21% greater than the US average CRC death rate. It is particularly concerning
that Oklahoman AIs have a staggering 63% greater incidence rates >51% higher mortality rates for CRC
than the national rate drawn mostly from Caucasian populations. Oklahoman AAs also have higher
incidence (~20%) and mortality (54.9%) compared to overall US mortality rates. At present no in-depth
studies have been performed to understand the risk factors that contribute to these CRC incidence and
mortality rates in Oklahoma’s AIs and AAs compared to Caucasians. Thus, this collaborative
administrative supplement focuses on understanding the genomic and metabolomic risk factors with
specific focus on the inflammation in CRC patients of AI, AA and Caucasian descent. Our collaborative
team includes laboratory based basic researchers (C.V. Rao, Ph.D; H. Yamada, Ph.D, K. Morris, M.D, C.
Xu, Ph.D,) and cancer disparities researchers M. Doescher, M.D, from the Stephenson Cancer Center
and Upender Manne, Ph.D, (University of Alabama, at Birmingham) the latter with expertise in AA cancer
disparities. Our specific goals in this administrative supplement are to establish whether: i) enhanced
genomic mutational burden; ii) altered gene expression; and iii) higher systemic and colonic inflammation
are key factors contributing to the higher incidence and mortality of Oklahoman AIs and AAs as compared
to Oklahoma Caucasian populations. The outcomes will provide a basis to develop novel anti-
inflammatory (R01 213987 specific objective) and immune targeted approaches as adjuvants to improve
disease free survival in AI and AA CRC patients.

## Key facts

- **NIH application ID:** 10260715
- **Project number:** 3R01CA213987-05S1
- **Recipient organization:** UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
- **Principal Investigator:** Chinthalapally V. Rao
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $217,481
- **Award type:** 3
- **Project period:** 2016-12-15 → 2023-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10260715

## Citation

> US National Institutes of Health, RePORTER application 10260715, Safer Approaches to CRC Chemoprevention (3R01CA213987-05S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10260715. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*